Mandate

Vinge assisted Industrifonden in connection with the sale of shares in Oncopeptides AB (publ) through an accelerated bookbuilding process

August 17, 2018

In total, 1,2 million shares were placed at a price of SEK 148 per share, corresponding to a total value of approximately SEK 178 million.

Following the transaction, Industrifonden holds approximately 23.67% of the shares in Oncopeptides.
 
Vinge’s team consisted of Dain Hård Nevonen, Rikard Lindahl and Sofie Bjärtun.

Related

Vinge has advised Sertion AB in connection with the acquisition of Svensk Anläggning och Driftteknik AB

Through the acquisition, Sertion takes a further step in its development as a leading international infrastructure and installation group within complex HVAC systems, technical infrastructure, and industrial piping. Svensk Anläggning och Driftteknik AB specializes in certified welding and installation of industrial piping.
February 10, 2026

Vinge advises Mirova in connection with the acquisition of the Boarp, Dållebo and Fågelås wind farms

Vinge has advised Mirova, a subsidiary of Natixis Investment Managers focusing on sustainable investments, in connection with the acquisition of the three Swedish onshore wind farms Boarp, Dållebo and Fågelås.
February 10, 2026

Vinge has advised Bridgepoint in its acquisition together with Polaris of a majority stake in PDSVISION, a global leader in digital engineering

Headquartered in Stockholm, PDSVISION operates across North America, Europe and Asia. The company delivers integrated software and services that support digital transformation in product development and manufacturing, helping customers improve productivity and accelerate the journey from concept to production. The company has built a subscription-led business with ~SEK 1.7 billion in revenues, characterised by longstanding customer relationships and strong organic growth.
February 10, 2026